Placebo News and Research

RSS

Emory MVA COVID-19 vaccine proven safe and effective in mice and monkeys

Researchers at Yerkes National Primate Research Center, Emory University, have developed a COVID-19 vaccine that has proven safe and effective in mice and monkeys.

4 Feb 2021

ZyCoV-D SARS-CoV-2 DNA vaccine shows robust immunogenicity and protective efficacy in Rhesus macaquesys

A team of scientists from India has recently tested the efficacy and immunogenicity of two different concentrations of a plasmid DNA-based vaccine candidate ZyCoV-D. The findings reveal that the vaccine candidate administered via Needle Free Injection System (NFIS) can significantly induce the production of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein-specific IgG and neutralizing antibodies for a prolonged period.

4 Feb 2021

Phase I/II trial findings support use of CoronaVac vaccine in older individuals

Researchers in China have reported phase I/II clinical trial findings showing that the vaccine candidate CoronaVac is well tolerated among older individuals and effectively generates antibody responses against severe acute respiratory syndrome coronavirus 2 (SARs-CoV-2) - the agent that causes coronavirus disease 2019 (COVID-19).

4 Feb 2021

Russia's Sputnik V COVID-19 shown to have 91.6 percent efficacy

The phase 3 human trial is the last stage of clinical evaluation, showing how effective and safe a drug or vaccine is. In this case, the Gam- Sputnik V showed a consistent strong protective effect across all participant age groups.

3 Feb 2021

Phase 1 clinical trial of novel HIV vaccine approach shows promising results

A phase 1 clinical trial testing a novel vaccine approach to prevent HIV has produced promising results, IAVI and Scripps Research announced today.

3 Feb 2021

Latest clinical trial supports UK’s decision to delay second COVID vaccine dose

Researchers in the UK, South Africa and Brazil have reported the latest efficacy results from phase III trials of the Oxford–AstraZeneca vaccine currently being rolled out in the UK to protect against coronavirus disease 2019 (COVID-19).

3 Feb 2021

Researchers report trial results of rectal microbicides at HIV R4P Virtual Conference

Researchers seeking to develop on-demand and behaviorally congruent HIV prevention options for people who practice anal sex are reporting the results of three early phase clinical trials of rectal microbicides at this week's HIV Research for Prevention (HIV R4P) Virtual Conference.

3 Feb 2021

J&J SARS-CoV-2 vaccine shows immunity in non-human primates 6 months after vaccination

A new preprint research paper released on the bioRxiv server discusses the findings from a model that assesses the association between the immunogenicity and protection conferred by a set of adenovirus- (Ad26)-vectored vaccines that express stabilized SARS-CoV-2 spike protein.

3 Feb 2021

Two-dose regimen of adenovirus-based vaccine offers 91.6% efficacy against COVID-19

An interim analysis of data from the phase 3 trial of the COVID-19 vaccine from Russia (Gam-COVID-Vac) suggests that a two-dose regimen of the adenovirus-based vaccine offers 91.6% efficacy against symptomatic COVID-19.

2 Feb 2021

Pfizer-BioNTech vaccine shows promise against new SARS-CoV-2 variants

A team of researchers in the U.S. studied the Pfizer-BioNTech vaccine candidate - currently being rolled out in many parts of the world to high-risk individuals - to see if it still holds up against mutant strains of the virus and yielded encouraging results.

2 Feb 2021

ACE2 agonist C21 relieves respiratory difficulty in COVID-19

A new study describes a pilot study on the efficacy of a molecule called C21, which enhances the activity of the angiotensin-converting enzyme 2 (ACE2), the host cell receptor that facilitates viral entry.

2 Feb 2021

When your chance for a covid shot comes, don’t worry about the numbers

When getting vaccinated against covid-19, there's no sense being picky. You should take the first authorized vaccine that's offered, experts say.

1 Feb 2021

Ivermectin may not be the ‘silver bullet’ antiviral against COVID-19

A team of researchers based in Peru and the U.S. recently examined the role of the anti-parasitic drug ivermectin in treating COVID-19.

1 Feb 2021

Colchicine may have therapeutic potential against COVID-19

A new study describes the results of colchicine in mitigating the inflammatory storm associated with COVID-19, and thus preventing a percentage of severe and critical cases.

1 Feb 2021

Nivolumab monotherapy is effective treatment option for relapsed malignant mesothelioma

Nivolumab monotherapy is an effective treatment option for relapsed malignant mesothelioma (MM), according to research presented today at the International Association for the Study of Lung Cancer World Conference on Lung Cancer.

31 Jan 2021

DSMB recommends continuation of Phase 2/3 study of opaganib for severe COVID-19

RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced that the independent Data Safety Monitoring Board (DSMB) for the global Phase 2/3 study of opaganib in patients with severe COVID-19, unanimously recommended to continue the study following a pre-scheduled futility review of unblinded efficacy data from the first 135 patients treated in the study and safety data from the first 175 patients.

30 Jan 2021

Fetal and neonatal therapy combination may lessen the aftereffects of congenital CMV infection

A cross-institutional research group has revealed for the first time in the world that infants with symptomatic congenital cytomegalovirus (CMV) infection who were treated with a combination of immunoglobulin fetal therapy and neonatal therapy with antiviral drugs were less likely to experience the severe aftereffects associated with the infection than those who only received the neonatal therapy.

28 Jan 2021